ResearcherJohns Hopkins UniversityNo recent work listed
Annie A. Wu
Matched on ORCID iD 0000-0002-0730-298X; OpenAlex author ID A5073746550. Sources: OpenAlex.
Their work
- Papers
- 9
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 45
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers
Papers 9
- Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000351↗
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
- A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
- An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
- Current Status of Immunotherapies for Treating Pancreatic Cancer. Co-author DOI 10.1007/s11912-019-0811-5↗
- Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Co-author DOI 10.1172/jci.insight.122857↗
- Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-1383↗
- Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Co-author DOI 10.1126/scisignal.aaa5823↗
- Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. Co-author DOI 10.3791/4059↗
Closest collaborators
The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elizabeth M. Jaffee · 8 shared papers, 2013–2020 · strength 0.62
- Paper Current Status of Immunotherapies for Treating Pancreatic Cancer. DOI 10.1007/s11912-019-0811-5↗
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Lei Zheng · 5 shared papers, 2013–2020 · strength 0.31
- Paper Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibi… DOI 10.1136/jitc-2019-000351↗
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. DOI 10.1158/0008-5472.can-16-1383↗
- Dung Thi Le · 3 shared papers, 2020 · strength 0.26
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Daniel A. Laheru · 3 shared papers, 2020 · strength 0.26
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Robert A. Anders · 4 shared papers, 2013–2020 · strength 0.25
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Paper Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. DOI 10.1126/scisignal.aaa5823↗
- Katherine M. Bever · 3 shared papers, 2013–2020 · strength 0.21
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in pati… DOI 10.18632/oncotarget.27586↗
- Paper Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. DOI 10.3791/4059↗
- Andrew H. Ko · 2 shared papers, 2020 · strength 0.17
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Elana Judith Fertig · 2 shared papers, 2020 · strength 0.17
- Paper A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatm… DOI 10.1158/1078-0432.ccr-20-1025↗
- Paper Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Pat… DOI 10.1158/1078-0432.ccr-19-3978↗
- Valerie Lee · 1 shared paper, 2019 · strength 0.16
- Elaine O. Bigelow · 2 shared papers, 2013–2020 · strength 0.12
- Kelly Foley · 2 shared papers, 2015–2017 · strength 0.10
- Agnieszka A. Rucki · 2 shared papers, 2015–2017 · strength 0.10
- Qian Xiao · 2 shared papers, 2015–2017 · strength 0.10
- Noelle R. Jurcak · 1 shared paper, 2020 · strength 0.09
- Ding Ding · 1 shared paper, 2020 · strength 0.09
- Kenji Fujiwara · 1 shared paper, 2020 · strength 0.09
- Brian T. Herbst · 1 shared paper, 2020 · strength 0.09
- Stephen T. Muth · 1 shared paper, 2020 · strength 0.09
- May Tun Saung · 1 shared paper, 2020 · strength 0.09
- Keyu Li · 1 shared paper, 2020 · strength 0.09
- Alex B. Blair · 1 shared paper, 2020 · strength 0.09
- Nan Niu · 1 shared paper, 2020 · strength 0.09
- Won Jin Ho · 1 shared paper, 2020 · strength 0.09
- Andrea Wang‐Gillam · 1 shared paper, 2020 · strength 0.09
- Lisa M. Coussens · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.